Promise of Cytogenetics in Tackling the Most Intractable Problems in Cancer Diagnosis, Therapy & Treatment to Drive the Global Molecular Cytogenetics Market
Epidemic spread of cancer, high patient unresponsiveness
to conventional therapy standards, and the promise of cytogenetics in tackling
the toughest challenges in battling cancer are poised to drive the global market for Molecular
Cytogenetics to reach US$2.3 billion
by 2022.
Molecular Cytogenetics refers to extensive studies
of chromosomal variation and abnormalities, and their relation to disease.
Cytogenetics plays an important role in identification of genetic
predisposition to disease and also a person’s reaction to a certain drug. Simpler cytogenetic technologies, such as Capillary
Electrophoresis (CE), first generation amplification, and PCR (Polymerase Chain
Reaction) have given way to advancements such as Fluorescence in Situ
Hybridization (FISH) as well as array-based technologies, in particular
array-based Comparative Genome Hybridization (aCGH). Advanced molecular
cytogenetic technologies have assumed an extremely significant role in medical
research. aCGH as a high-resolution tool that offers the unique ability of
performing thousands of experiments in one array is fast replacing FISH
technology, with advantages in terms of rapid and accurate diagnosis.
Cytogenetic
techniques aid pathologists in diagnosis and prognosis related to solid tumors
and hematological malignancies. With the increasing incidence of cancer worldwide,
the scope of molecular cytogenetics is increasing. Better understanding of the
relation between certain chromosomal anomalies and cancers has necessitated
their detection through multiplex or multicolor Fluorescence In Situ
Hybridization
(multiplex FISH). Whole-genome tools, such as microarrays and next-generation
sequencing (NGS), enable the study of the whole genome from a few malignant
cells, at a resolution and precision high enough to detect abnormalities and
consider potential rearrangements. Apart from improving quality of care and
treatment, molecular cytogenetics also assist physicians in developing
personalized therapies by leveraging the concepts of pharmacogenomics and
pharmacogenetics. Demand for higher-resolution chromosomal analysis stands to
benefit from research studies linking chromosomal abnormality to autism,
schizophrenia, as well as cancer.
As
stated by the new market research report on Molecular Cytogenetics, the United States
represents the largest market worldwide. Asia-Pacific ranks as the fastest
growing market with a CAGR of 27.4% over the analysis period. The growth in the
region is led by growing population, high disease prevalence, unmet needs in
effective disease diagnosis, rise in chromosome abnormalities due to unchecked
and uncontrolled pollution in emerging economies, and growing per capita
healthcare spending in developing countries like China and India.
Major players in the market include Abbott
Molecular, Agilent Technologies Inc., Applied Spectral Imaging, Biological
Industries, Bio-Rad Laboratories Inc., Cytognomix Inc., CytoTest Inc., F.
Hoffmann-La Roche Ltd., Illumina Inc., Leica Biosystems Nussloch GmbH, Oxford
Gene Technology, PerkinElmer Inc., SciGene Corporation, and Thermo Fisher
Scientific Inc., among others.
The research report titled "Molecular Cytogenetics –
Market Analysis, Trends, and Forecasts" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth
drivers, mergers and acquisitions, and other strategic industry activities of
major companies worldwide. The report provides market estimates and projections
for geographic markets, such as the US, Canada, Japan, Europe (France, Germany,
Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China and Rest of
Asia-Pacific) and Rest of World. Technology segments analyzed for the market
include FISH (Fluorescent In Situ Hybridization) and Array-based Technologies.
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
For cutting edge analyst reviews on top industries
Follow
us on Twitter; Connect with us on
LinkedIn;
Follow us on Medium
Comments
Post a Comment